Medical weight loss treatments have gained massive popularity worldwide, especially injectable medications that help regulate appetite and metabolism. Drugs containing semaglutide, the active ingredient in globally known injections like Ozempic and Wegovy, have become some of the most prescribed treatments for obesity and metabolic health.
However, these medications are often expensive in many countries, including India. That situation is expected to change significantly in March 2026, when the patent for semaglutide expires in India. After this expiry, several Indian pharmaceutical companies plan to launch lower-cost generic versions of these weight loss injections, potentially reducing treatment costs by up to 50–60%.
These upcoming launches could make advanced weight loss therapies much more accessible to patients across India.
Semaglutide belongs to a class of medications called GLP-1 receptor agonists, which mimic natural hormones that regulate hunger and blood sugar levels.
These medications help patients lose weight by:
Because of these effects, semaglutide injections have become one of the most widely used weight loss medications globally.
Before discussing the new Indian brands, it is important to understand the current injections available in India, which are mostly foreign products.
| Injection | Active Ingredient | Approx Weekly Price |
|---|---|---|
| Wegovy | Semaglutide | ₹17,000 – ₹26,000 |
| Ozempic | Semaglutide | ₹15,000 – ₹20,000 |
| Mounjaro | Tirzepatide | ₹20,000+ |
These injections are effective but expensive, which limits accessibility for many patients in India.
Once the semaglutide patent expires, several Indian companies are preparing to launch their own generic versions of the drug, significantly lowering costs. Here are some Indian brands that are expected to enter the market.
Sun Pharmaceutical Industries has received regulatory approval to manufacture and sell generic semaglutide in India. The company plans to launch the drug under the brand name Noveltreat for weight loss treatment. Sun Pharma will also market a related semaglutide formulation under another brand called Sematrinity for diabetes treatment.
Expected Price: Estimated ₹4,000 – ₹6,000 per week
Potentially 50–60% cheaper than imported brands
Dr. Reddy’s Laboratories is preparing to launch a generic semaglutide injection that may be sold under the brand name Obeda. The company plans to produce millions of injection pens annually.
Expected Price: Around 50–60% lower than current imported injections
Estimated ₹4,500 – ₹6,000 per week
The company is reportedly planning to distribute around 12 million pens in the first year.
Zydus Lifesciences is also entering the market with three semaglutide brands: Semaglyn, Mashema, and Alterme. These injections will use a reusable adjustable injection pen, which may further reduce treatment costs for patients.
Expected Price: Estimated ₹3,500 – ₹5,000 per week
The reusable pen design allows patients to adjust dosage levels without needing multiple disposable pens.
Another semaglutide option already introduced in India is Poviztra, marketed through a partnership between Novo Nordisk and Emcure Pharmaceuticals. This injection is a 2.4 mg semaglutide dose designed for weight loss treatment.
Estimated Price: Around ₹20,000+ per month
Although still relatively expensive, this launch expanded access to semaglutide therapy in India before generic versions arrive.
India is known as one of the largest pharmaceutical manufacturing hubs in the world. When patents expire, local companies can produce generic versions of blockbuster drugs at much lower prices.
The expiration of the semaglutide patent in March 2026 is expected to trigger intense competition among pharmaceutical companies. This competition will likely lead to:
For many patients who previously could not afford GLP-1 injections, these generics could make treatment more realistic.
India is experiencing rising rates of obesity and metabolic disorders. As awareness grows about advanced medical treatments, more people are seeking clinically supervised weight loss programs.
With the arrival of affordable semaglutide injections, the Indian medical weight loss market is expected to grow rapidly over the next few years.
Healthcare providers offering GLP-1 therapy, nutritional counseling, and metabolic health programs may see increased demand as these treatments become more accessible.
Although these medications are highly effective, they should always be used under medical supervision. Improper use can lead to side effects or complications.
At specialized centers like MOH Clinics, patients can receive personalized guidance on advanced weight loss treatments, including GLP-1 injections and metabolic health programs.
A professional consultation ensures that treatment is tailored to the patient’s health history, lifestyle, and weight loss goals.
The launch of affordable generic semaglutide injections in India could transform the weight loss treatment landscape. With several major pharmaceutical companies preparing to introduce their own brands after the 2026 patent expiry, patients may soon have access to advanced therapies at significantly lower prices.
Indian brands such as Noveltreat, Obeda, Semaglyn, Mashema, and Alterme are expected to compete with global medications like Ozempic and Wegovy, making medical weight loss treatments more accessible to a broader population.
As these therapies become widely available, medically supervised weight management programs will play a crucial role in ensuring safe and sustainable results.
Consult with our experts at MOH Clinics to explore how advanced weight loss therapies and personalized programs can help you achieve your health goals safely.
Book Consultation